Skip to main content
Manasi Vaidya on Muck Rack

Manasi Vaidya

Verified
New York
As seen in: GlobalData, Pharmaceutical-Technology.com, MSN, Nature, Yahoo Finance, Yahoo, Nautilus, Yahoo Finanzas, Clinical Trials Arena, Medical Device Network, Investment Monitor, Fuentitech
Healthcare reporter and editor @PharmaTechFocus @globaldataplc, NYU SHERP alum, past @NautilusMag @NatureMedicine Film trivia junkie.

Get in touch with Manasi

Contact Manasi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Manasi Vaidya’s Journalist Portfolio

See all →
Roche's IMpower010 trial results warrant evidence for Tecentriq adoption

Roche's IMpower010 trial results warrant evidence for Tecentriq adoption

The adoption of Roche's Tecentriq (atezolizumab) as an adjuvant treatment in non-small cell lung cancer (NSCL…

View article →
UK observational Covid-19 long-hauler study including paediatrics

UK observational Covid-19 long-hauler study including paediatrics

A 1,200-participant observational study to gather information on immune profiles among Covid-19 long-haulers …

View article →
Covid-19 antibody cocktail trials employ varied variant-tracking strategies

Covid-19 antibody cocktail trials employ varied variant-tracking strategies

Ongoing Covid-19 trials are adopting different strategies to sequence patient samples to identify the impact …

View article →
Angion ANG-3777 prior data, multitargeted MOA well-placed to tackle DGF

Angion ANG-3777 prior data, multitargeted MOA well-placed to tackle DGF

Angion Biomedica's bid to treat delayed graft function (DGF) following kidney transplantation is strong with …

View article →
NIH's ACTIV-4 enrolls COVID-19 patients to explore antiplatelet addition to antithrombotic drugs

NIH's ACTIV-4 enrolls COVID-19 patients to explore antiplatelet addition to antithrombotic drugs

The NIH's ACTIV-4 trial has enrolled 400 patients to evaluate the addition of an antiplatelet to antithrombot…

View article →
NIH's COVID-19 ACTIV-2 to begin exploration of postinfection immunisation strategies

NIH's COVID-19 ACTIV-2 to begin exploration of postinfection immunisation strategies

NIH's ACTIV-2 trial is set to start a substudy to evaluate the ideal vaccination strategy after infection amo…

View article →

Articles

Medtech clinical trials navigate macro trends and regulatory changes Original

|
By Manasi Vaidya Verified
| Clinical Trials Arena Verified
PhaseV’s technology harnesses advanced causal inference and machine learning to identify subtle patterns in clinical data. Credit: raker/Shutterstock. An upcoming conference will investigate the latest trends in the medical devices and medtech clinical trials industry with a focus on navigating recent regulatory changes.
Open in Who Shared View Duplicates (4) Issue with article?

Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials

|
By Manasi Vaidya Verified
| Yahoo Finance Verified
A constantly evolving landscape for clinical trials and drug development research has created challenges for the sector to not only keep up with changes but also to plan ahead for potential developments. Recent changes in guidelines for trials issued by the US Food and Drug Administration (FDA) have necessitated contract research organisations (CROs), pharma sponsors, biotechs and clinical investigators to adapt quickly to ensure a successful program.
Open in Who Shared View Duplicates (3) Issue with article?

OCT West Coast: China’s clinical trial infrastructure delivers upto 60% cost savings Original

|
By Manasi Vaidya Verified
| Clinical Trials Arena Verified
Revati Tatake, Global head of Pharma and Competitive Intelligence, GlobalData, speaks about the latest clinical trial, drug development and licensing trends from China at the Outsourcing in Clinical Trials West Coast 2026 conference. Image credit: Arena International China’s rise as a source of innovative drugs is being driven by clinical trial environment that is proving to be a cost-effective and rapid option on the global stage, as per discussions at a recent event.
Open in Who Shared View Duplicates (2) Issue with article?
See all 250 articles